Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.

@article{Koido2014TreatmentWC,
  title={Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.},
  author={Shigeo Koido and Sadamu Homma and Masato Okamoto and Kazuki Takakura and Masako Mori and Shinji Yoshizaki and Shintaro Tsukinaga and Shunichi Odahara and Seita Koyama and Hiroo Imazu and Kan Uchiyama and Mikio Kajihara and Hiroshi Arakawa and Takeyuki Misawa and Yoichi Toyama and Satoru Yanagisawa and Masahiro Ikegami and S B Jennifer Kan and Kazumi Hayashi and Hideo Komita and Yuko Kamata and Masaki Ito and Takefumi Ishidao and Sei-ichi Yusa and Shigetaka Shimodaira and Jianlin Gong and Haruo Sugiyama and Toshifumi Ohkusa and Hisao Tajiri},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 16},
  pages={4228-39}
}
PURPOSE We performed a phase I trial to investigate the safety, clinical responses, and Wilms' tumor 1 (WT1)-specific immune responses following treatment with dendritic cells (DC) pulsed with a mixture of three types of WT1 peptides, including both MHC class I and II-restricted epitopes, in combination with chemotherapy. EXPERIMENTAL DESIGN Ten stage IV patients with pancreatic ductal adenocarcinoma (PDA) and 1 patient with intrahepatic cholangiocarcinoma (ICC) who were HLA-positive for A*02… CONTINUE READING
Highly Cited
This paper has 74 citations. REVIEW CITATIONS